AI assistant
ANGIODYNAMICS INC — Director's Dealing 2021
Feb 3, 2021
32939_dirs_2021-02-03_599decb2-6373-4e17-8638-24ce11bfab95.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ANGIODYNAMICS INC (ANGO)
CIK: 0001275187
Period of Report: 2021-02-01
Reporting Person: ROSENZWEIG RICHARD C (SVP and General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-01 | Common Stock | A | 11000 | — | Acquired | 11000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-01 | Non-Qualified Stock Option (right to buy) | $18.92 | A | 62000 | Acquired | 2031-02-01 | Common Stock (62000) | Direct |
Footnotes
F1: The acquisition of 11,000 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 11,000 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on February 1, 2022, such that 25% of the restricted stock units will vest on each of February 1, 2022, 2023, 2024 and 2025.
F2: These stock options vest in four equal annual installments beginning on February 1, 2022, such that 25% of the options will vest on each of February 1, 2022, 2023, 2024 and 2025.